

## IN THE CLAIMS

Please amend claims 1, 5-7, 10, 20, 24, 28-30, and 36 as indicated below.

1. (Currently Amended) A method for ~~modulating~~ lowering triglyceride levels in a subject in need thereof, comprising:  
identifying a subject having elevated triglyceride levels; and  
administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.
2. (Previously Presented) The method according to claim 1 wherein said exendin or exendin agonist is administered continuously.
3. (Previously Presented) The method according to claim 1 wherein said administration is by injection.
4. (Previously Presented) The method according to claim 3 wherein the injection is a subcutaneous injection.
5. (Currently Amended) The method according to claim 1 wherein about 1  $\mu\text{g}$   $[[\text{-}30\mu\text{g}]]$  to about 1 mg of the exendin or exendin agonist is administered per day.
6. (Currently Amended) The method according to claim 1 wherein about 1  $\mu\text{g}$   $[[\text{-}30\mu\text{g}]]$  to about 500  $\mu\text{g}$  of the exendin or exendin agonist is administered per day.
7. (Currently Amended) The method according to claim 1 wherein about 1  $\mu\text{g}$   $[[\text{-}30\mu\text{g}]]$  to about 100  $\mu\text{g}$  of the exendin or exendin agonist is administered per day.
8. (Previously Presented) The method according to claim 1, wherein about 3  $\mu\text{g}$  to about 50  $\mu\text{g}$  of the exendin or exendin agonist is administered per day.
9. (Previously Presented) The method of claim 1 wherein said subject is human.
10. (Currently Amended) A method for ~~modulating~~ lowering plasma triglyceride concentrations in a subject with heart disease, comprising:  
identifying a patient with heart disease having elevated triglyceride levels; and  
administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.
11. (Previously Presented) The method according to any of claims 1-10 wherein said exendin is exendin-3.

12. (Previously Presented) The method according to any of claim 1-10 wherein said exendin is exendin-4.
13. (Previously Presented) The method according to any of claims 1-10 wherein said exendin agonist is selected from the group consisting of exendin-4 acid, exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4, and <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 (1-28) amide.
14. (Previously Presented) The method according to any of claims 1-10 wherein said exendin agonist is an exendin analog or derivative.
15. (Previously Presented) The method according to any of claims 1-10, further comprising administering a therapeutically effective amount of a statin.
16. (Withdrawn) The method according to any of claims 1-10 wherein said exendin agonist is an exendin agonist according to Formula I.
17. (Withdrawn) The method according to any of claims 1-10 wherein said exendin agonist is an exendin agonist according to Formula II.
18. (Withdrawn) The method according to any of claims 1-10 wherein said exendin agonist is an exendin agonist according to Formula III.
19. (Previously Presented) A method for treating dyslipidemia in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.
20. (Previously Presented) The method according to claim 19 wherein said exendin agonist is an exendin analog or derivative.
21. (Withdrawn) The method according to claim 19 wherein said exendin agonist is an exendin agonist according to Formula I.
22. (Withdrawn) The method according to claim 19 wherein said exendin agonist is an exendin agonist according to Formula II.
23. (Withdrawn) The method according to claim 19 wherein said exendin agonist is an exendin agonist according to Formula III.
24. (Currently Amended) A method for ~~modulating~~ lowering postprandial triglyceride levels in a subject in need thereof, comprising:  
identifying a subject having elevated postprandial triglyceride levels; and

administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.

25. (Previously Presented) The method according to claim 24 wherein said exendin or exendin agonist is administered continuously.

26. (Previously Presented) The method according to claim 24 wherein said administration is by injection.

27. (Previously Presented) The method according to claim 26 wherein the injection is a subcutaneous injection.

28. (Currently Amended) The method according to claim 24 wherein about 1 µg [[-30 µg]] to about 1 mg of the exendin or exendin agonist is administered per day.

29. (Currently Amended) The method according to claim 24 wherein about 1 µg [[-30 µg]] to about 500 µg of the exendin or exendin agonist is administered per day.

30. (Currently Amended) The method according to claim 24 wherein about 1 µg [[-30 µg]] to about 100 µg of the exendin or exendin agonist is administered per day.

31. (Previously Presented) The method according to claim 24, wherein about 3 µg to about 50 µg of the exendin or exendin agonist is administered per day.

32. (Previously Presented) The method of claim 24 wherein said subject is human.

33. (Previously Presented) The method according to any of claims 24-32 wherein said exendin is exendin-3.

34. (Previously Presented) The method according to any of claim 24-32 wherein said exendin is exendin-4.

35. (Previously Presented) The method according to any of claims 24-32 wherein said exendin agonist is selected from the group consisting of exendin-4 acid, exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, <sup>14</sup>Leu,<sup>25</sup>Phe exendin-4, and <sup>14</sup>Leu,<sup>25</sup>Phe exendin-4 (1-28) amide.

36. (Previously Presented) The method according to any of claims 24-32 wherein said exendin agonist is an exendin analog or derivative.

37. (Previously Presented) The method according to any of claims 24-32, further comprising administering a therapeutically effective amount of a statin.

38. (Withdrawn) The method according to any of claims 24-32 wherein said exendin agonist is an exendin agonist according to Formula I.

39. (Withdrawn) The method according to any of claims 24-32 wherein said exendin agonist is an exendin agonist according to Formula II.

40. (Withdrawn) The method according to any of claims 24-32 wherein said exendin agonist is an exendin agonist according to Formula III.

41. (Previously Presented) The method according to claim 1 wherein said exendin or exendin agonist is selected from the group consisting of exendin-3, exendin-4, exendin-4 acid, exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4, and <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 (1-28) amide.